Nurnberg H George, Hensley Paula L, Gelenberg Alan J, Fava Maurizio, Lauriello John, Paine Susan
Department of Psychiatry, Health Sciences Center,University of New Mexico School of Medicine, 2400 Tucker NE, Albuquerque, NM 87131-5288, USA.
JAMA. 2003 Jan 1;289(1):56-64. doi: 10.1001/jama.289.1.56.
Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance.
To assess the efficacy of sildenafil citrate in men with sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitor (SRI) antidepressants.
DESIGN, SETTING, AND PATIENTS: Prospective, parallel-group, randomized, double-blind, placebo-controlled trial conducted between November 1, 2000, and January 1, 2001, at 3 US university medical centers among 90 male outpatients (mean [SD] age, 45 [8] years) with major depression in remission and sexual dysfunction associated with SRI antidepressant treatment.
Patients were randomly assigned to take sildenafil (n = 45) or placebo (n = 45) at a flexible dose starting at 50 mg and adjustable to 100 mg before sexual activity for 6 weeks.
The primary outcome measure was score on the Clinical Global Impression-Sexual Function (CGI-SF); secondary measures were scores on the International Index of Erectile Function, Arizona Sexual Experience Scale, Massachusetts General Hospital-Sexual Functioning Questionnaire, and Hamilton Rating Scale for Depression (HAM-D).
Among the 90 randomized patients, 93% (83/89) of patients treated per protocol took at least 1 dose of study drug and 85% (76/89) completed week 6 end-point assessments with last observation carried forward analyses. At a CGI-SF score of 2 or lower, 54.5% (24/44) of sildenafil compared with 4.4% (2/45) of placebo patients were much or very much improved (P<.001). Erectile function, arousal, ejaculation, orgasm, and overall satisfaction domain measures improved significantly in sildenafil compared with placebo patients. Mean depression scores remained consistent with remission (HAM-D score < or =10) in both groups for the study duration.
In our study, sildenafil effectively improved erectile function and other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antidepressants. These improvements may allow patients to maintain adherence with effective antidepressant treatment.
性功能障碍是抗抑郁药常见的不良反应,常导致治疗依从性不佳。
评估枸橼酸西地那非对使用选择性和非选择性5-羟色胺再摄取抑制剂(SRI)类抗抑郁药所致性功能障碍男性患者的疗效。
设计、地点和患者:2000年11月1日至2001年1月1日在美国3所大学医学中心进行的一项前瞻性、平行组、随机、双盲、安慰剂对照试验,90例男性门诊患者(平均[标准差]年龄45[8]岁),患有缓解期重度抑郁症且伴有SRI类抗抑郁药治疗相关的性功能障碍。
患者被随机分配服用西地那非(n = 45)或安慰剂(n = 45),起始灵活剂量为50mg,可在性活动前调整至100mg,持续6周。
主要结局指标为临床总体印象-性功能(CGI-SF)评分;次要指标为国际勃起功能指数、亚利桑那性体验量表、麻省总医院性功能问卷和汉密尔顿抑郁量表(HAM-D)评分。
在90例随机分组的患者中,93%(83/89)按方案治疗的患者至少服用了1剂研究药物,85%(76/89)完成了第6周的终点评估,并采用末次观察结转分析。CGI-SF评分为2或更低时,西地那非组54.5%(24/44)的患者有很大或非常大的改善,而安慰剂组为4.4%(2/45)(P<0.001)。与安慰剂组患者相比,西地那非组患者的勃起功能、性唤起、射精、性高潮和总体满意度领域的指标有显著改善。在研究期间,两组的平均抑郁评分均保持在缓解水平(HAM-D评分≤10)。
在我们的研究中,西地那非有效改善了使用SRI类抗抑郁药所致性功能障碍男性患者的勃起功能和性功能的其他方面。这些改善可能使患者能够维持有效的抗抑郁治疗依从性。